XEDAR activates the non-canonical NF-κB pathway

Area of Science:

• Immunology
• Cell Biology
• Molecular Biology

Background:

• The tumor necrosis factor receptor (TNFR) superfamily regulates diverse cellular processes.
• X-linked ectodermal dysplasia receptor (XEDAR) is a TNFR member, binding ectodysplasin-A2 (EDA-A2).
• XEDAR's precise molecular functions remain incompletely understood despite its discovery in 2000.

Purpose of the Study:

• To investigate the intracellular signaling pathways activated by XEDAR.
• To elucidate the role of XEDAR in the non-canonical nuclear factor κB (NF-κB) pathway.
• To identify the molecular components and regulators of XEDAR-mediated signaling.

Main Methods:

• Stimulation of cells expressing XEDAR.
• Analysis of NF-κB pathway activation, including p100 processing and nuclear translocation of p52 and RelB.
• Co-immunoprecipitation assays to assess protein-protein interactions (XEDAR, TRAF3, TRAF6).
• Kinase inhibition assays to evaluate the roles of NIK and IKKα.

Main Results:

• XEDAR activates the non-canonical NF-κB pathway, leading to p100 processing into p52.
• XEDAR binding to TRAF3 and TRAF6 is essential for p100 processing.
• NIK and IKKα kinase activity are required for XEDAR-induced p100 processing.
• XEDAR stimulation leads to NIK accumulation.
• TRAF3, cIAP1, and A20 negatively regulate XEDAR-induced p100 processing.

Conclusions:

• XEDAR triggers the non-canonical NF-κB pathway through a mechanism involving TRAF3, TRAF6, NIK, and IKKα.
• This study reveals a novel signaling role for XEDAR in regulating NF-κB2 (p100/p52) processing.
• Understanding XEDAR's signaling provides insights into TNFR superfamily functions and ectodermal development.